Taxol Adjuvant Indication Should Refer To Receptor Status Effect On Efficacy
The indication for Bristol-Myers Squibb's Taxol should refer physicians to the "clinical studies" section of labeling for information about receptor subgroup analyses, FDA's Oncologic Drugs Advisory Committee said Sept. 17 in recommending sequential administration of Taxol (paclitaxel) following chemotherapy for node-positive breast cancer.
You may also be interested in...
Bristol-Myers Squibb's Taxol (paclitaxel) approval for sequential adjuvant therapy allows for use of the drug in estrogen and progesterone receptor-negative and positive tumors, although no benefit has been made clear in the receptor-positive group.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011